$BLUE
bluebird bio, Inc.

2017 Q1 Form 10-K Financial Statement

#000156459017002015 Filed on February 22, 2017

View on sec.gov

Income Statement

Concept 2017 Q1 2015 Q4 2015 Q3
Revenue $6.832M $1.471M $1.324M
YoY Change 355.77% -76.97% -79.2%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $20.30M $14.40M $13.70M
YoY Change 26.88% 171.7% 107.58%
% of Gross Profit
Research & Development $55.00M $35.70M $30.40M
YoY Change 31.23% 74.15% 82.59%
% of Gross Profit
Depreciation & Amortization $2.840M $2.040M $1.870M
YoY Change 24.56% 22.16% 21.43%
% of Gross Profit
Operating Expenses $76.75M $50.43M $44.45M
YoY Change 30.34% 95.47% 166.99%
Operating Profit -$69.91M -$48.96M -$43.13M
YoY Change 21.84% 149.62% 153.54%
Interest Expense $1.556M $1.300M -$400.0K
YoY Change -255.6% -750.0% 300.0%
% of Operating Profit
Other Income/Expense, Net -$355.0K $100.0K $300.0K
YoY Change -136.94% 0.0% -1600.0%
Pretax Income -$68.71M -$47.30M -$42.90M
YoY Change 21.79% 142.56% 151.91%
Income Tax $0.00 $0.00 $100.0K
% Of Pretax Income
Net Earnings -$68.71M -$47.28M -$42.92M
YoY Change 22.1% 141.9% 152.05%
Net Earnings / Revenue -1005.74% -3213.94% -3241.99%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.684M -$1.289M -$1.179M
COMMON SHARES
Basic Shares Outstanding 40.84M
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q1 2015 Q4 2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $634.1M $517.9M $707.5M
YoY Change 14.64% 9.35% 228.46%
Cash & Equivalents $216.0M $164.3M $417.5M
Short-Term Investments $418.1M $353.7M $290.0M
Other Short-Term Assets $3.285M $6.000M $5.700M
YoY Change -58.42% -6.25% -27.85%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $667.3M $524.0M $713.2M
YoY Change 18.95% 9.16% 219.36%
LONG-TERM ASSETS
Property, Plant & Equipment $181.7M $82.61M $61.60M
YoY Change 88.1% 424.87% 311.27%
Goodwill $13.13M
YoY Change 0.0%
Intangibles $24.46M
YoY Change -13.33%
Long-Term Investments $165.8M $347.8M $194.2M
YoY Change -39.44% 1790.22% 301.24%
Other Assets $24.90M $10.36M $10.20M
YoY Change 133.02% 752.67% 777.8%
Total Long-Term Assets $405.3M $478.4M $304.4M
YoY Change -2.97% 523.29% 184.82%
TOTAL ASSETS
Total Short-Term Assets $667.3M $524.0M $713.2M
Total Long-Term Assets $405.3M $478.4M $304.4M
Total Assets $1.073B $1.002B $1.018B
YoY Change 9.59% 80.04% 208.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.800M $6.334M $3.500M
YoY Change 180.61% 114.42% -3.87%
Accrued Expenses $37.50M $23.10M $19.50M
YoY Change 60.94% 81.89% 101.03%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $72.60M $40.37M $33.60M
YoY Change 86.31% -6.07% -12.78%
LONG-TERM LIABILITIES
Long-Term Debt $147.6M $61.90M $43.80M
YoY Change 98.39%
Other Long-Term Liabilities $37.00M $237.0K $50.50M
YoY Change -37.07% -19.39% 15534.67%
Total Long-Term Liabilities $184.6M $237.0K $94.30M
YoY Change 38.59% -19.39% 29095.05%
TOTAL LIABILITIES
Total Short-Term Liabilities $72.60M $40.37M $33.60M
Total Long-Term Liabilities $184.6M $237.0K $94.30M
Total Liabilities $257.2M $151.8M $128.6M
YoY Change 49.36% 131.88% 88.28%
SHAREHOLDERS EQUITY
Retained Earnings -$314.2M
YoY Change 113.16%
Common Stock $369.0K
YoY Change 14.24%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $815.4M $850.5M $889.0M
YoY Change
Total Liabilities & Shareholders Equity $1.073B $1.002B $1.018B
YoY Change 9.59% 80.04% 208.18%

Cashflow Statement

Concept 2017 Q1 2015 Q4 2015 Q3
OPERATING ACTIVITIES
Net Income -$68.71M -$47.28M -$42.92M
YoY Change 22.1% 141.9% 152.05%
Depreciation, Depletion And Amortization $2.840M $2.040M $1.870M
YoY Change 24.56% 22.16% 21.43%
Cash From Operating Activities -$75.30M -$33.09M -$29.06M
YoY Change 104.79% 111.3% 39.91%
INVESTING ACTIVITIES
Capital Expenditures $26.02M -$3.440M -$1.050M
YoY Change 568.31% 42.74% -40.68%
Acquisitions
YoY Change
Other Investing Activities $21.57M -$217.7M -$148.7M
YoY Change -68.44% -825.77% -14.46%
Cash From Investing Activities -$4.450M -$221.2M -$149.7M
YoY Change -106.9% -901.38% -14.73%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $3.040M
YoY Change 375.74%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 16.87M 1.020M 3.000M
YoY Change 2535.94% -99.59% -97.28%
NET CHANGE
Cash From Operating Activities -75.30M -33.09M -29.06M
Cash From Investing Activities -4.450M -221.2M -149.7M
Cash From Financing Activities 16.87M 1.020M 3.000M
Net Change In Cash -62.88M -253.2M -175.8M
YoY Change -322.03% -198.06% 104.13%
FREE CASH FLOW
Cash From Operating Activities -$75.30M -$33.09M -$29.06M
Capital Expenditures $26.02M -$3.440M -$1.050M
Free Cash Flow -$101.3M -$29.65M -$28.01M
YoY Change 149.17% 123.77% 47.42%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
10360000
CY2015Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
28145000
CY2015Q4 us-gaap Assets
Assets
1002337000
CY2016 dei Document Period End Date
DocumentPeriodEndDate
2016-12-31
CY2016 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
CY2016 dei Amendment Flag
AmendmentFlag
false
CY2016 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2016 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2016 dei Document Type
DocumentType
10-K
CY2017Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
40844757
CY2016 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2016 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2016 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2016 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2016Q2 dei Entity Public Float
EntityPublicFloat
1586834900
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
164269000
CY2015Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
353680000
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6016000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
523965000
CY2015Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
347814000
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
82614000
CY2015Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
24456000
CY2015Q4 us-gaap Goodwill
Goodwill
13128000
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6334000
CY2015Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
5889000
CY2016 dei Trading Symbol
TradingSymbol
BLUE
CY2016 dei Entity Registrant Name
EntityRegistrantName
bluebird bio, Inc.
CY2016 dei Entity Central Index Key
EntityCentralIndexKey
0001293971
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-48709000
CY2015Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
8294000
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
40368000
CY2015Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
35959000
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
60000
CY2014 us-gaap License And Services Revenue
LicenseAndServicesRevenue
390000
CY2014 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
19474000
CY2014 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5049000
CY2014 us-gaap Share Based Goods And Nonemployee Services Transaction Stockholders Equity
ShareBasedGoodsAndNonemployeeServicesTransactionStockholdersEquity
42000
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10763000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
491257000
CY2014 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
23295000
CY2015 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
22753000
CY2015Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
5082000
CY2016Q4 blue Construction Financing Obligation
ConstructionFinancingObligation
120140000
CY2015Q4 blue Construction Financing Obligation
ConstructionFinancingObligation
61901000
CY2015Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
237000
CY2015Q4 us-gaap Liabilities
Liabilities
151841000
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
369000
CY2015Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1166585000
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2291000
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-314167000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
850496000
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1002337000
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36894000
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36894000
CY2014 us-gaap Available For Sale Securities Change In Net Unrealized Holding Gain Loss Net Of Tax
AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLossNetOfTax
-71000
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-7.07
CY2015 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.81
CY2014 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.83
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37284000
CY2015 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
34669000
CY2014 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26546000
CY2015 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2220000
CY2014 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-71000
CY2016 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1142000
CY2015 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2220000
CY2016 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-262365000
CY2016 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
600000
CY2015 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
151667000
CY2014 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
353042000
CY2014 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-11797000
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
41120000
CY2016 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
15269000
CY2015 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
477247000
CY2015 us-gaap Available For Sale Securities Change In Net Unrealized Holding Gain Loss Net Of Tax
AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLossNetOfTax
-2220000
CY2016 us-gaap Depreciation And Amortization
DepreciationAndAmortization
9648000
CY2016 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
234731000
CY2016 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6145000
CY2016 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
677000
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
39756000
CY2016 us-gaap Available For Sale Securities Change In Net Unrealized Holding Gain Loss Net Of Tax
AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLossNetOfTax
1142000
CY2016 blue Fair Value Of Contingent Consideration Non Cash
FairValueOfContingentConsiderationNonCash
2675000
CY2015 blue Fair Value Of Contingent Consideration Non Cash
FairValueOfContingentConsiderationNonCash
2344000
CY2014 blue Fair Value Of Contingent Consideration Non Cash
FairValueOfContingentConsiderationNonCash
246000
CY2015 us-gaap Depreciation And Amortization
DepreciationAndAmortization
7419000
CY2014 us-gaap Depreciation And Amortization
DepreciationAndAmortization
4228000
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
39756000
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
41120000
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
10763000
CY2014 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
168000
CY2014 blue Noncash Benefit On Release Of Income Tax Valuation Allowance
NoncashBenefitOnReleaseOfIncomeTaxValuationAllowance
11797000
CY2016 us-gaap Other Noncash Expense
OtherNoncashExpense
2825000
CY2015 us-gaap Other Noncash Expense
OtherNoncashExpense
1513000
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
14318000
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6847000
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
6658000
CY2015 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2541000
CY2016 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
20889000
CY2015 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
9423000
CY2016 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
4565000
CY2015 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
11171000
CY2016 blue Increase Decrease In Deferred Rent Payable
IncreaseDecreaseInDeferredRentPayable
1162000
CY2015 blue Increase Decrease In Deferred Rent Payable
IncreaseDecreaseInDeferredRentPayable
-330000
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-189647000
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-98429000
CY2016 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
4379000
CY2015 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
8816000
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
15995000
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7055000
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8708000
CY2016 us-gaap Payments For Tenant Improvements
PaymentsForTenantImprovements
12034000
CY2016 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
348225000
CY2016 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
443364000
CY2014 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
4673000
CY2016 blue Payments Of Contingent Purchase Price Consideration
PaymentsOfContingentPurchasePriceConsideration
2025000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
206279000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
241534000
CY2015 blue Payments Of Contingent Purchase Price Consideration
PaymentsOfContingentPurchasePriceConsideration
453000
CY2016 blue Proceeds From Reimbursement Of Tenant Improvements For Capital Lease
ProceedsFromReimbursementOfTenantImprovementsForCapitalLease
1663000
CY2016 blue Proceeds From Public Offering Of Common Stock Net Of Issuance Costs
ProceedsFromPublicOfferingOfCommonStockNetOfIssuanceCosts
234962000
CY2015 blue Proceeds From Public Offering Of Common Stock Net Of Issuance Costs
ProceedsFromPublicOfferingOfCommonStockNetOfIssuanceCosts
477064000
CY2014 blue Proceeds From Public Offering Of Common Stock Net Of Issuance Costs
ProceedsFromPublicOfferingOfCommonStockNetOfIssuanceCosts
353226000
CY2016 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6934000
CY2015 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
10109000
CY2014 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5226000
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
486720000
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
358452000
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
114618000
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-183576000
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
141566000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
347845000
CY2016 blue Construction Financing Obligation Non Cash
ConstructionFinancingObligationNonCash
48034000
CY2015 blue Construction Financing Obligation Non Cash
ConstructionFinancingObligationNonCash
61901000
CY2016 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
6363000
CY2015 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2089000
CY2014 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
387000
CY2016 blue Tenant Improvements Under Capital Lease Included In Prepaid Expenses And Other Assets
TenantImprovementsUnderCapitalLeaseIncludedInPrepaidExpensesAndOtherAssets
8542000
CY2016 blue Deferred Stock Offering Costs Included In Accounts Payable And Accrued Liabilities
DeferredStockOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities
231000
CY2014 blue Deferred Stock Offering Costs Included In Accounts Payable And Accrued Liabilities
DeferredStockOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities
183000
CY2016 us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Description of the business </p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:2.27%;">bluebird bio, Inc. (the &#8220;Company&#8221; or &#8220;bluebird&#8221;) was incorporated in Delaware on April&#160;16, 1992, and is headquartered in Cambridge, Massachusetts. The Company researches, develops, manufactures and plans to commercialize gene therapies for severe genetic diseases and cancer. Since its inception, the Company has devoted substantially all of its resources to its research and development efforts relating to its product candidates, including activities to manufacture product candidates, conduct clinical studies of its product candidates, perform preclinical research to identify new product candidates and provide general and administrative support for these operations. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:2.27%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June&#160;30, 2014, the Company acquired all of the outstanding capital stock of Precision Genome Engineering, Inc. (&#8220;Pregenen&#8221;) and in connection therewith, obtained the rights to Pregenen&#8217;s gene editing and cell signaling technology. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:2.27%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2014, the Company sold 3,450,000 shares of common stock (inclusive of 450,000 shares of common stock sold by the Company pursuant to the full exercise of an overallotment option granted to the underwriters in connection with the offering) through an underwritten public offering at a price of $34.00 per share for aggregate net proceeds of $109.8 million. In December 2014, the Company sold 3,047,500 shares of common stock (inclusive of 397,500 shares of common stock sold by the Company pursuant to the full exercise of an overallotment option granted to the underwriters in connection with the offering) through an underwritten public offering at a price of $85.00 per share for aggregate net proceeds of $243.3 million.&nbsp;&nbsp;In June 2015, the Company sold 2,941,176, shares of common stock through an underwritten public offering at a price of $170.00 per share for aggregate net proceeds of $477.2 million.&nbsp;&nbsp;In December 2016, the Company sold 3,289,473 shares of common stock through an underwritten public offering at a price of $76.00 per share for aggregate net proceeds of $234.7 million.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:2.27%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2016, the Company had cash, cash equivalents and marketable securities of $884.8 million. Although the Company has incurred recurring losses and expects to continue to incur losses for the foreseeable future, the Company expects its cash, cash equivalents and marketable securities will be sufficient to fund current operations for at least the next twelve months. </p></div>
CY2016 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:2.27%;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements. Estimates are used in the following areas, among others: acquisition-date fair value and subsequent fair value estimates used to assess potential impairment of long-lived assets, including goodwill and intangible assets, construction financing lease obligations, contingent consideration, stock-based compensation expense, accrued expenses, revenue and income taxes.</p></div>
CY2016 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of credit risk and off-balance sheet risk </p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:2.27%;">Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents and available-for-sale securities. The Company maintains its cash and cash equivalent balances with high-quality financial institutions and, consequently, the Company believes that such funds are subject to minimal credit risk. The Company&#8217;s available-for-sale investments primarily consist of U.S. Treasury securities, U.S. government agency securities and certificates of deposit, and potentially subject the Company to concentrations of credit risk. The Company has adopted an investment policy which limits the amounts the Company may invest in any one type of investment and requires all investments held by the Company to be at least AA+/Aa1 rated, thereby reducing credit risk exposure. </p></div>
CY2016 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
1992-04-16
CY2014Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
3450000
CY2014Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
3047500
CY2015Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
2941176
CY2016Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
3289473
CY2014Q3 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
109800000
CY2014Q4 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
243300000
CY2015Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
477200000
CY2016Q4 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
234700000
CY2014Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
34.00
CY2014Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
85.00
CY2015Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
170.00
CY2016Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
76.00
CY2014Q3 blue Stock Issued During Period Shares Overallotment Options Exercised
StockIssuedDuringPeriodSharesOverallotmentOptionsExercised
450000
CY2014Q4 blue Stock Issued During Period Shares Overallotment Options Exercised
StockIssuedDuringPeriodSharesOverallotmentOptionsExercised
397500
CY2016Q4 us-gaap Investments And Cash
InvestmentsAndCash
884800000
CY2016 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2016 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2015 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2014 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2016Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2015Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2016Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
606481000
CY2015Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
703785000
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
40000
CY2015Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
22000
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
578000
CY2015Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2313000
CY2016Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
605943000
CY2015Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
701494000
CY2016Q4 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
884830000
CY2016Q4 us-gaap Liabilities Fair Value Disclosure Recurring
LiabilitiesFairValueDisclosureRecurring
7756000
CY2015Q4 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
865763000
CY2015Q4 us-gaap Liabilities Fair Value Disclosure Recurring
LiabilitiesFairValueDisclosureRecurring
8665000
CY2016 us-gaap Additional Cash And Cash Equivalent Related Text
AdditionalCashAndCashEquivalentRelatedText
Three months or less
CY2016 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2015 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2016 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
0
CY2015 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
0
CY2016Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
376100000
CY2015Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
4472000
CY2015Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
638100000
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
169399000
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
89435000
CY2016Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
95500000
CY2015Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
0
CY2016Q4 us-gaap Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held
OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld
0
CY2015Q4 us-gaap Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held
OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld
0
CY2016Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
4479000
CY2015Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
3584000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
12444000
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6821000
CY2016 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5900000
CY2015 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3700000
CY2014 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2300000
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
11296000
CY2016Q4 blue Accrued Goods And Services
AccruedGoodsAndServices
34275000
CY2016Q4 blue Accrued License And Milestone Fees
AccruedLicenseAndMilestoneFees
2464000
CY2015Q4 blue Accrued License And Milestone Fees
AccruedLicenseAndMilestoneFees
277000
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1014000
CY2015Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
964000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
643000
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
495000
CY2016Q4 us-gaap Accrued Bonuses Current And Noncurrent
AccruedBonusesCurrentAndNoncurrent
4900000
CY2013Q2 us-gaap Lessee Leasing Arrangements Operating Leases Term Of Contract
LesseeLeasingArrangementsOperatingLeasesTermOfContract
P9Y
CY2013Q2 blue Area Of Leased Space
AreaOfLeasedSpace
43600
CY2013Q2 blue Lease Amendment Effective Month And Year
LeaseAmendmentEffectiveMonthAndYear
2014-06
CY2013Q2 blue Additional Lease Space Agreement
AdditionalLeaseSpaceAgreement
9900
CY2013Q2 us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
200000
CY2014Q4 us-gaap Operating Leases Rent Expense Contingent Rentals
OperatingLeasesRentExpenseContingentRentals
300000
CY2013Q2 blue Landlord Contribution For Leasehold Improvements
LandlordContributionForLeaseholdImprovements
7800000
CY2013Q2 blue Letter Of Credit Related To New Lease Agreement
LetterOfCreditRelatedToNewLeaseAgreement
1300000
CY2016Q4 blue Letter Of Credit Related To New Lease Agreement
LetterOfCreditRelatedToNewLeaseAgreement
600000
CY2015Q4 blue Letter Of Credit Related To New Lease Agreement
LetterOfCreditRelatedToNewLeaseAgreement
600000
CY2013Q2 blue Lease Starting Date
LeaseStartingDate
2013-06-03
CY2016 blue Lease Termination Date
LeaseTerminationDate
2017-04-12
CY2016Q4 blue Contractual Obligation Agreement Period
ContractualObligationAgreementPeriod
P5Y
CY2016Q4 blue Contractual Obligation Agreement Renewal Period
ContractualObligationAgreementRenewalPeriod
P3Y
CY2016Q4 blue Contractual Obligation Fees
ContractualObligationFees
3000000
CY2016Q4 blue Contractual Obligation Advance Fees Payment
ContractualObligationAdvanceFeesPayment
2000000
CY2016Q4 blue Contractual Obligation Fees Payable
ContractualObligationFeesPayable
1000000
CY2016Q4 us-gaap Maintenance Costs
MaintenanceCosts
9800000
CY2016Q4 blue Contractual Obligation Termination Description
ContractualObligationTerminationDescription
Company may terminate this agreement with six months’ notice and a one-time termination fee prior to July 1, 2018, or twelve months’ notice and a one-time termination fee thereafter.
CY2016 blue Tenant Improvement Costs Not Reimbursable
TenantImprovementCostsNotReimbursable
1800000
CY2016Q4 blue Future Minimum Commitments Due Current
FutureMinimumCommitmentsDueCurrent
26424000
CY2016Q4 blue Future Minimum Commitments Due In Two Years
FutureMinimumCommitmentsDueInTwoYears
29015000
CY2016Q4 blue Future Minimum Commitments Due In Three Years
FutureMinimumCommitmentsDueInThreeYears
28815000
CY2016Q4 blue Future Minimum Commitments Due In Four Years
FutureMinimumCommitmentsDueInFourYears
29146000
CY2016Q4 blue Future Minimum Commitments Due In Five Years
FutureMinimumCommitmentsDueInFiveYears
29484000
CY2016Q4 blue Future Minimum Commitments Due Thereafter
FutureMinimumCommitmentsDueThereafter
141600000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-53931000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-4436000
CY2015 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
5700000
CY2014 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
4300000
CY2016Q4 blue Future Minimum Commitments Due
FutureMinimumCommitmentsDue
284484000
CY2016 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
8300000
CY2016 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Common stock are entitled to one vote per share
CY2016Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
5433000
CY2014Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
3763000
CY2014Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
3763000
CY2014Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
3763000
CY2014Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
3763000
CY2014Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
3763000
CY2014Q2 blue Finite Lived Intangible Assets Amortization Expense Year Six
FiniteLivedIntangibleAssetsAmortizationExpenseYearSix
1879000
CY2014Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
20694000
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Other Increases Decreases In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod
1500000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1200000
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
39756000
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
41120000
CY2014 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10763000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.743
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.726
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.823
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M24D
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.015
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.017
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.018
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
15300000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
147900000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
41400000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
34.22
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
74.65
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
18.53
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
600000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3532000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1047000
CY2016 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
377000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
467000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3735000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1926000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
3735000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
48.74
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
52.09
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
16.30
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
55.04
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
52.17
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
39.23
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
52.17
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y6M
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y6M
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
93081000
CY2016Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
70991000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
93081000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-210188000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-162287000
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-61118000
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
612000
CY2014 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
1000
CY2015 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
60000
CY2016 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-588000
CY2014 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-9390000
CY2016 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-24000
CY2014 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-2408000
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2014 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2016 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.033
CY2015 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.042
CY2014 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.040
CY2016 blue Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.053
CY2015 blue Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.064
CY2014 blue Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.032
CY2016 blue Effective Income Tax Rate Reconciliation Tax Credits Research And Development
EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment
0.150
CY2015 blue Effective Income Tax Rate Reconciliation Tax Credits Research And Development
EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment
0.146
CY2014 blue Effective Income Tax Rate Reconciliation Tax Credits Research And Development
EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment
0.257
CY2016 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.070
CY2015 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.010
CY2014 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.000
CY2016 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.000
CY2015 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.005
CY2014 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.000
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.399
CY2015 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.449
CY2014 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.410
CY2016 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.001
CY2015 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2014 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.195
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
106064000
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
62844000
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
194000
CY2016Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
87117000
CY2015Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
47386000
CY2016Q4 blue Deferred Tax Assets Capitalized Research And Development Expenses
DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses
631000
CY2015Q4 blue Deferred Tax Assets Capitalized Research And Development Expenses
DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses
979000
CY2016Q4 blue Deferred Tax Assets Capital Lease
DeferredTaxAssetsCapitalLease
47191000
CY2015Q4 blue Deferred Tax Assets Capital Lease
DeferredTaxAssetsCapitalLease
24315000
CY2016Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
18231000
CY2015Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
16438000
CY2016Q4 blue Deferred Tax Assets Capitalized License Fees
DeferredTaxAssetsCapitalizedLicenseFees
11752000
CY2015Q4 blue Deferred Tax Assets Capitalized License Fees
DeferredTaxAssetsCapitalizedLicenseFees
5488000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
32172000
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
19486000
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
303158000
CY2015Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
177130000
CY2016Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
8129000
CY2015Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
9606000
CY2016Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
48902000
CY2015Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
26681000
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
246127000
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
140843000
CY2016 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
105300000
CY2016Q3 us-gaap Revenues
Revenues
1552000
CY2016Q4 us-gaap Revenues
Revenues
1552000
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
58879000
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
61527000
CY2016Q3 us-gaap Operating Expenses
OperatingExpenses
79692000
CY2016Q4 us-gaap Operating Expenses
OperatingExpenses
73887000
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-78140000
CY2016Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-72335000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-77025000
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
-71364000
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4009000
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3683000
CY2014 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4108000
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.07
CY2016Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.88
CY2015Q1 us-gaap Revenues
Revenues
6344000
CY2015Q2 us-gaap Revenues
Revenues
4940000
CY2015Q3 us-gaap Revenues
Revenues
1324000
CY2015Q4 us-gaap Revenues
Revenues
1471000
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
31270000
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
56963000
CY2015Q3 us-gaap Operating Expenses
OperatingExpenses
44451000
CY2015Q4 us-gaap Operating Expenses
OperatingExpenses
50432000
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-24926000
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-52023000
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-43127000
CY2015Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-48961000
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-24787000
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-51795000
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-42924000
CY2015Q4 us-gaap Net Income Loss
NetIncomeLoss
-47277000
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.76
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.57
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.18
CY2015Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.29

Files In Submission

Name View Source Status
0001564590-17-002015-index-headers.html Edgar Link pending
0001564590-17-002015-index.html Edgar Link pending
0001564590-17-002015.txt Edgar Link pending
0001564590-17-002015-xbrl.zip Edgar Link pending
blue-10k_20161231.htm Edgar Link pending
blue-20161231.xml Edgar Link completed
blue-20161231.xsd Edgar Link pending
blue-20161231_cal.xml Edgar Link unprocessable
blue-20161231_def.xml Edgar Link unprocessable
blue-20161231_lab.xml Edgar Link unprocessable
blue-20161231_pre.xml Edgar Link unprocessable
blue-ex1027_717.htm Edgar Link pending
blue-ex1031_718.htm Edgar Link pending
blue-ex1032_716.htm Edgar Link pending
blue-ex1044_719.htm Edgar Link pending
blue-ex1045_720.htm Edgar Link pending
blue-ex107_780.htm Edgar Link pending
blue-ex211_10.htm Edgar Link pending
blue-ex231_8.htm Edgar Link pending
blue-ex311_9.htm Edgar Link pending
blue-ex312_7.htm Edgar Link pending
blue-ex321_6.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g201702222116589526297.jpg Edgar Link pending
g201702222116589706297.jpg Edgar Link pending
g201702222117014286562.jpg Edgar Link pending
g201702222117014416563.jpg Edgar Link pending
g201702222117014546564.jpg Edgar Link pending
g201702222117014676565.jpg Edgar Link pending
g201702222117014806566.jpg Edgar Link pending
g201702222117014936567.jpg Edgar Link pending
g201702222117015066568.jpg Edgar Link pending
g201702222117015206569.jpg Edgar Link pending
g201702222117015336570.jpg Edgar Link pending
g201702222117015466571.jpg Edgar Link pending
g201702222117015596572.jpg Edgar Link pending
g201702222117015726573.jpg Edgar Link pending
g201702222117015856574.jpg Edgar Link pending
g201702222117015986575.jpg Edgar Link pending
g201702222117016136576.jpg Edgar Link pending
g201702222117016296577.jpg Edgar Link pending
g201702222117016416578.jpg Edgar Link pending
g201702222117016546579.jpg Edgar Link pending
g201702222117016676580.jpg Edgar Link pending
g201702222117016846581.jpg Edgar Link pending
g201702222117016976582.jpg Edgar Link pending
g201702222117017106583.jpg Edgar Link pending
g201702222117017226584.jpg Edgar Link pending
g201702222117017356585.jpg Edgar Link pending
g201702222117017476586.jpg Edgar Link pending
g201702222117017626587.jpg Edgar Link pending
g201702222117017766588.jpg Edgar Link pending
g201702222117017896589.jpg Edgar Link pending
g201702222117018016590.jpg Edgar Link pending
g201702222117018146591.jpg Edgar Link pending
g201702222117018266592.jpg Edgar Link pending
g201702222117018376593.jpg Edgar Link pending
g201702222117018496594.jpg Edgar Link pending
g201702222117018616595.jpg Edgar Link pending
g201702222117018746596.jpg Edgar Link pending
g201702222117018856597.jpg Edgar Link pending
g201702222117018986598.jpg Edgar Link pending
g201702222117019226599.jpg Edgar Link pending
g201702222117119107058.jpg Edgar Link pending
g201702222117119227059.jpg Edgar Link pending
g201702222117251607060.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending